Patient recruitment rate in IBD clinical trials significantly increased when using CT-SCOUT™ web application
Paris, France, February 11, 2020 – Clinical Trials Mobile Application (CTMA), a French start-up that specializes in the development of digital solutions for clinical research, today announces that it will present two posters detailing the results of its CT-SCOUT™ platform during the annual meeting of the European Crohn’s and Colitis Organization (ECCO), February 12-15, in Vienna (Austria). CT-SCOUT™ is a digital solution aimed at enhancing patient recruitment in clinical trials.
In a prospective, multicenter, open-label, observational and comparative study in 134 sites involving 644 patients in six countries (France, Belgium, Germany, Spain, the UK and Israel), the randomization rate increased by 2.8-fold in sites equipped with CT-SCOUT™ when compared with non-equipped sites. In patients with Ulcerative Colitis (UC), the randomization rate increased by a factor of 4 and in patients with Crohn’s Disease (CD), it increased by a factor of 1.9. All these increases are highly significant.
In a second study, the results of the use of the app in a phase 3 Inflammatory Bowel Disease (IBD) program in France showed that sites equipped with CT-SCOUT™ randomized significantly more patients than those non-equipped. In sites with the CT-SCOUT™ Premium mode (all functionalities of the app), randomization increased by 4.5-fold as compared to non-equipped sites and by 1.6 as compared to the sites with Freemium study mode (limited functionalities of the app).
CTMA, created in 2014, developed CT-SCOUT™, an innovative pre-screening digital solution, to allow physicians to detect relevant patients for ongoing on-site clinical studies in real time. Designed by doctors for doctors and clinical research teams, CT-SCOUT™ is a multiplatform web application that enables any doctor to become a potential recruiter. Beyond detecting eligible patients, it also facilitates the coordination of the research team in just a few clicks.
CT-SCOUT™’s proprietary technology is based on a unique algorithm designed by CTMA; pre-screening activities become much more accurate and time-effective. The tool, which is customized for each center, includes all academic and industry-sponsored studies running at the site. It reminds on-site medical professionals of all ongoing recruitment activities and their discriminating elements. Patient relevant data is available at their fingertips within a minute.
The specific pre-screening metrics help sponsors put in place remediation strategies. The use of CT-SCOUT™ has proven to increase on-site recruitment rates and reduce the duration of the clinical trials, and therefore the time and cost it takes to get to market.
Patients will benefit from more opportunity to obtain better treatment options, as they will have faster access to new molecules.
“The main barrier to validating new molecules in the field of IBD is insufficient patient enrollment in clinical trials, resulting in premature termination of trials and increased costs,” said Laurent Peyrin-Biroulet, president of GETAID (Groupe d’Etude Therapeutique des Affections Inflammatoires du Tube Digestif) and elected president of the ECCO organization. “CT-SCOUT™ is important for patients because it facilitates their enrollment in clinical trials. Before CT-SCOUT™ we missed out on a lot of patients; we now have dramatically increased enrollments into our studies. We have reported this widely, which has clearly increased our visibility at national and international levels.”
“In recent international prospective observational IBD trials, patient recruitment tripled in centers equipped with the CTMA solution, compared to unequipped centers,” said Norman Sabbah, COO of CTMA. “CTMA stands out from the competition because its technology is based on a unique algorithm. It offers all the studies on one platform, along with a research team coordination system and a dashboard that gives sponsors visibility on the center’s activity in terms of patient recruitment. Our offering is unique in that it is, to our knowledge, the sole tool that has consistently demonstrated its ability to enhance recruitment in successive clinical trials.”
CT-SCOUT™ is currently deployed in ten countries, with more than 150 equipped centers and 6,000 patients detected. In the coming years, CTMA plans to open the solution to new therapeutic areas including oncology, cardiology and neurology.
CTMA strives to continuously provide sponsors and clinical trial sites with the best digital pre-screening solutions to facilitate patients’ detection and inclusion in clinical studies. With its solution, it is committed to helping physicians and on-site study teams save time by making their contribution as simple and efficient as possible. This not only accelerates the completion of clinical trials and reduces the time to market, but also facilitates patients’ access to the potential of new therapeutic innovations.